Stoke Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Stoke Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2018 to Q3 2024.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $7.49M, a 14.4% increase year-over-year.
  • Stoke Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $26.4M, a 5.6% increase year-over-year.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25.3M, a 10.5% increase from 2022.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $22.9M, a 38.9% increase from 2021.
  • Stoke Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $16.5M, a 185% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $26.4M $7.49M +$942K +14.4% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $25.4M $7.43M +$667K +9.87% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $24.8M $5.41M -$477K -8.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 $25.3M $6.06M +$268K +4.63% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 $25M $6.55M +$626K +10.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $24.4M $6.76M +$597K +9.69% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $23.8M $5.89M +$912K +18.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $22.9M $5.79M +$1.1M +23.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 $21.8M $5.93M +$1.31M +28.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $20.4M $6.16M +$1.71M +38.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $18.7M $4.98M +$2.28M +84.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $16.5M $4.69M +$3.11M +197% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 $13.3M $4.61M +$2.83M +158% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $10.5M $4.45M +$2.8M +170% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $7.71M $2.7M +$1.94M +258% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $5.77M $1.58M +$868K +122% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 $4.9M $1.79M +$1.05M +144% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $3.85M $1.65M +$1.35M +453% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $2.5M $754K +$573K +317% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.92M $712K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 $731K +$691K +1728% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $298K +$221K +287% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $181K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q3 2018 $40K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $77K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.